- Home
- Publications
- Publication Search
- Publication Details
Title
CDK9 inhibitors in acute myeloid leukemia
Authors
Keywords
Acute myeloid leukemia, CDK9 inhibitor, Positive transcription elongation factor b, P-TEFb, <em class=EmphasisTypeItalic >MCL-1</em>, <em class=EmphasisTypeItalic >MYC</em>
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-23
DOI
10.1186/s13046-018-0704-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies
- (2017) Øystein Bruserud et al. Expert Opinion on Drug Discovery
- CDK9: A key player in cancer and other diseases
- (2017) Lia Carolina Franco et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
- (2017) Ranjan Bista et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
- (2016) Shao Xie et al. ACTA PHARMACOLOGICA SINICA
- Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
- (2016) Arne Scholz et al. CANCER RESEARCH
- Overview of CDK9 as a target in cancer research
- (2016) Fatima Morales et al. CELL CYCLE
- Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells
- (2016) Yuanmei Zhai et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
- (2016) Yogesh A. Sonawane et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
- (2016) Tinghu Zhang et al. Nature Chemical Biology
- Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
- (2016) Monica Pallis et al. Oncotarget
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- Abstract 3400: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL1 dependency in responder bone marrow
- (2015) Elisha J. Dettman et al. CANCER RESEARCH
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2015) Ryan D. Cassaday et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
- (2015) S G T Devaraj et al. LEUKEMIA
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
- (2015) Joshua F. Zeidner et al. LEUKEMIA RESEARCH
- Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study
- (2015) Hai-Xiao Jin et al. PLoS One
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
- (2015) Elisabeth Walsby et al. Oncotarget
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
- (2014) Chun-Hao Huang et al. GENES & DEVELOPMENT
- Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
- (2014) William E. Pierceall et al. LEUKEMIA RESEARCH
- A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
- (2014) T. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
- (2014) Gaëlle Mariaule et al. MOLECULES
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
- (2013) D. Thomas et al. BLOOD
- Outcome of older patients with acute myeloid leukemia
- (2013) Mya S. Thein et al. CANCER
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
- (2013) Ivana Gojo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Super-Enhancers in the Control of Cell Identity and Disease
- (2013) Denes Hnisz et al. CELL
- BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
- (2013) W. E. Pierceall et al. MOLECULAR CANCER THERAPEUTICS
- HEXIM1, a New Player in the p53 Pathway
- (2013) Qiao Lew et al. Cancers
- The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells
- (2012) Monica Pallis et al. BRITISH JOURNAL OF HAEMATOLOGY
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
- (2012) Victoria Del Gaizo Moore et al. CANCER LETTERS
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
- (2012) J. E. Karp et al. HAEMATOLOGICA
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
- (2011) J. E. Karp et al. BLOOD
- CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol
- (2011) Xiangrui Liu et al. INTERNATIONAL JOURNAL OF CANCER
- TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
- (2011) K C Goh et al. LEUKEMIA
- The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
- (2011) E Walsby et al. LEUKEMIA
- Flavopiridol inducesBCL-2expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia
- (2011) Dwella M. Nelson et al. LEUKEMIA & LYMPHOMA
- 55K isoform of CDK9 associates with Ku70 and is involved in DNA repair
- (2010) Hongbing Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases
- (2010) Gaetano Romano et al. CELL CYCLE
- Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
- (2010) Zhifu Xiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
- (2009) Rong Chen et al. BLOOD
- CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3′-end processing
- (2009) Judith Pirngruber et al. EMBO REPORTS
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
- (2009) Judith E. Karp et al. LEUKEMIA RESEARCH
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia
- (2009) Dorothee Mueller et al. PLOS BIOLOGY
- The multi-tasking P-TEFb complex
- (2008) Vanessa Brès et al. CURRENT OPINION IN CELL BIOLOGY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More